Brian Davis
University Hospitals of Cleveland
28 Papers
475 Citations
Brian Davis is an academic researcher from University Hospitals of Cleveland. The author has contributed to research in topics: Viral vector & Genetic enhancement. The author has an hindex of 18, co-authored 28 publications. Previous affiliations of Brian Davis include Case Western Reserve University.
Chat about Author
Papers
•Journal Article
Selection for G156A O6-Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Protection from Lethality in Mice Treated with O6-Benzylguanine and 1,3-Bis(2-chloroethyl)-1-nitrosourea
TL;DR: In this paper, a retroviral gene therapy approach was developed to protect early hematopoietic progenitors from 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a stem cell toxin, and O 6-benzylguanine (BG), an inhibitor of a key BCNU resistance protein, O 6alkylguansine DNA alkyltransferase (AGT).
117
p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation.
Eugenia V. Broude,Swift Me,Claire Vivo,Bey-Dih Chang,Brian Davis,S Kalurupalle,Mikhail V. Blagosklonny,Igor B. Roninson +7 more
TL;DR: It is shown that ectopic p21 expression in human HT1080 fibrosarcoma cells causes not only dephosphorylation but also depletion of Rb, suggesting negative feedback regulation of damage-induced cell-cycle checkpoint arrest.
83
Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
Xiaobin Lu,Laurent Humeau,Vladimir Slepushkin,Gwendolyn K. Binder,Yu Qiao,Tatiana Slepushkina,Ziping Chen,Randall K. Merling,Brian Davis,Chang Yung-Nien,Boro Dropulic +10 more
TL;DR: It is demonstrated that there is no significant in vivo vector mobilization using a primary SCID‐hu mouse transplantation model, which correlates with the presence of an anti‐HIV payload and suggests that inclusion of antisense may be a useful tool to restrict mobilization in other vector constructs.
80
•Journal Article
Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance
TL;DR: Gene transfer of drug resistance genes will have broad applications in the field of gene therapy as well as in protecting hematopoietic cells from chemotherapy toxicity.
71
In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication.
TL;DR: Efficient ex vivo and in vivo selection for hematopoietic cells transduced with lentiviral vectors are established and support the potential therapeutic benefit of this strategy in human gene therapy.
51